Kandesartancileksetil/Amlodipin/Hidroklorotiazid Adamed

Candesartan cilexetil, amlodipine, and hydrochlorothiazide, the active ingredients in Kandesartancileksetil/Amlodipin/Hidroklorotiazid Adamed, are an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic presented as oral tablets for oral use. They are prescribed to lower elevated blood pressure in adult patients with hypertension. GNH USA supplies Kandesartancileksetil/Amlodipin/Hidroklorotiazid Adamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kandesartancileksetil/Amlodipin/Hidroklorotiazid Adamed is used to manage hypertension, a condition characterized by elevated arterial pressure.

Hypertension: reduces systolic and diastolic blood pressure and lowers the risk of cardiovascular events. Isolated systolic hypertension: improves pulse pressure control in older adults. Essential hypertension: provides a convenient fixed‑dose option for patients requiring multiple antihypertensive mechanisms.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache or mild flushing. - Peripheral edema, particularly of the ankles. - Increased urination or mild electrolyte changes. - Fatigue or mild muscle cramps. - Dry mouth or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Acute kidney injury or marked rise in serum creatinine. - Hyperkalemia or severe electrolyte imbalance. - Angioedema involving face, lips, tongue, or airway. - Pancreatitis or severe abdominal pain. - Hepatic dysfunction or jaundice.

Before initiating therapy, patients should be evaluated for renal function, electrolyte status, and potential drug allergies.

Monitor blood pressure regularly: adjust dose if target not achieved. Assess renal function: check serum creatinine and eGFR at baseline and periodically. Check electrolytes: especially potassium and sodium levels. Use caution in hepatic impairment: dose may need adjustment. Avoid in patients with known hypersensitivity to any component. Store at below 25°C: keep in the original pack, protect from moisture.

When combined with certain medicines, the risk of adverse events may increase.

Major Interactions (Avoid): - Concomitant ACE inhibitors or other ARBs: risk of hyperkalemia and renal failure. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and impair renal function. - Cyclosporine or tacrolimus: may increase serum creatinine. - Lithium: risk of lithium toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise amlodipine levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower amlodipine exposure. - Other antihypertensives (beta‑blockers, ACE inhibitors): additive blood‑pressure lowering effect. - Antidiabetic agents: blood‑glucose control may improve, requiring dose adjustment. - Anticoagulants (warfarin): monitor INR as blood‑pressure changes can affect anticoagulation stability.